6 Quotes by John Boris

We believe the downside risk from current levels is limited anchored by Merck offering an attractive 4.4% dividend.

There could be a much higher rate of suicide with people not taking their medications, than with people taking their medication.

We expect the price spread to increase from 28% to more than 70% with additional generic launches.

The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected.

Anything that hints of a weaker top line doesn't play too well with the Street. We believe there's a tad bit of disconnect, and the modest contraction in the stock has created a good buying opportunity.

An anticipation ruling would depend largely on how Judge Stein interprets certain wording within the patent. It adds some risk.